Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713204 · ClinicalTrials.gov registry record · Phase 2
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Phase 2 study of Neovascular Age-related Macular Degeneration, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 365
- Enrollment target
- 20
- Study locations
NCT02713204 is a Phase 2 study of Neovascular Age-related Macular Degeneration that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 365 participants, roughly in line with the 398-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target. The trial reports 20 study locations across 3 states.
The verdict
NCT02713204, a Phase 2 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 365 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
Conditions Studied
Interventions
- DRUG REGN910-3
- DRUG Intravitreal Aflibercept Injection (IAI)
Study Locations (20)
California
- Regeneron Investigational Site - Arcadia
- Regeneron Investigational Site - Bakersfield
- Regeneron Investigational Site - Beverly Hills
- Regeneron Investigational Site - Encino
- Regeneron Investigational Site 1 - Los Angeles
- Regeneron Investigational Site 2 - Los Angeles
- Regeneron Investigational Site - Mountain View
- Regeneron Investigational Site - Oceanside
- Regeneron Investigational Site 1 - Palm Desert
- Regeneron Investigational Site 2 - Palm Desert
- Regeneron Investigational Site - Palo Alto
- Regeneron Investigational Site - Poway
- Regeneron Investigational Site - Redlands
- Regeneron Investigational Site - Sacramento
Arizona
- Regeneron Investigational Site 1 - Phoenix
- Regeneron Investigational Site 2 - Phoenix
- Regeneron Investigational Site 3 - Phoenix
- Regeneron Investigational Site 1 - Tucson
- Regeneron Investigational Site 2 - Tucson
Alabama
- Regeneron Investigational Site - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2016-03-31 |
| Est. Completion | 2017-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02713204
The ClinicalTrials.gov registry entry for NCT02713204 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 398-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which REGN910-3 is the first listed.
NCT02713204 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02713204 about?
NCT02713204 is a clinical study titled "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection". The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
What is the current status of trial NCT02713204?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 365 participants. The study started on 2016-03-31. Estimated completion is 2017-10-03.
What conditions does trial NCT02713204 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT02713204?
The interventions under investigation include: REGN910-3 (DRUG), Intravitreal Aflibercept Injection (IAI) (DRUG).
Who is sponsoring clinical trial NCT02713204?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02713204 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
COMPLETED · Phase 2
-
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.